Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great presentation today, and the stock rallied 25%, good stuff, will continue to skimm off the top a bit and buy on pullbacks, I dont see this going to the moon quickly, but who knows.
nice move today and nobody is paying attention as usual, skimmed a little off but have absolutely huge position here and the float is small. While SIGY hasnt participated in pennymania, its time is coming, pennymania or not. This is a steal if it falls back to the 1.20 range.
Webinar presentation on the 16th may be worth listening in on.
Ok so the fda said they can start human studies fantastic. So maybe a couple years for fda approval
2 questions guys when was the patent filed and just anyones guess when it might be granted. Also does this need fda approved.
this is just fantastic at these prices, what a steal, wait till this takes off, its found money. I will keep buying and buying and buying at this price.
got filled at 1.10 and 1.05 in a quick drop, only way to get these fills is to have GTC order in. CEO just did an interview worth listening to:
https://wallstreetanalyzer.com/2021/01/18/sigyn-therapeutics-inc-otcmarkets-sigy/
$SIGY Sigyn Therapeutics (SIGY) CEO Note: Overcoming the Limitations of Previous Cytokine Storm Treatment Strategies
Press Release | 01/12/2021
SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), today released the following note authored by its Chairman and CEO, Jim Joyce.
Dear Current and Candidate Shareholders,
We created Sigyn Therapy to address a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome (the Cytokine Storm). An annual market opportunity that exceeds $20 billion.
Based on our cumulative experience in developing first-in-industry medical technologies, we designed Sigyn Therapy to overcome the limitations of previous strategies to treat cytokine storm related conditions, yet still optimize patient safety and support widespread deployment.
As anti-cytokine drug mechanisms are limited to single cytokine targets, our focus was directed toward overcoming the limitations of two industry pioneering devices that are market cleared and broadly deployed to treat life-threatening inflammatory conditions outside of the U.S. At present, both of these devices are being evaluated in the U.S. as candidates to treat severe COVID-19 infection.
The first device incorporates an adsorbent bead to address inflammatory cytokines that circulate freely in the blood. However, this device does not address endotoxin, which is a potent activator of cytokine storm syndrome. Conversely, the second device depletes the presence of circulating endotoxin, but does not address inflammatory cytokines. The cytokine device underlies a Nasdaq traded company whose market value is ~$385 million. The endotoxin device is among a family of products marketed by an OTC traded company valued at almost $10 billion.
Since establishing ourselves as a public company on October 19, 2020, we have made considerable progress in collecting relevant data that reinforces the prospect of Sigyn Therapy overcoming the limitations of these products.
On November 2, 2020, I authored my first CEO note entitled: “Rethinking the Treatment of Sepsis and Other Life-Threatening Inflammatory Conditions.” The note disclosed that we had initiated an in vitro study to validate whether Sigyn Therapy could reduce the presence of inflammatory cytokines and endotoxin from human blood plasma.
On December 1, 2020, we reported in vitro study results that validated the ability of Sigyn Therapy to simultaneously clear both inflammatory cytokines and endotoxin from human blood plasma. Beyond reporting this milestone achievement, we disclosed our intent to further evaluate the ability of Sigyn Therapy to address CytoVesicles (extracellular vesicles) that transport inflammatory cytokine cargos throughout the bloodstream.
On January 6, 2021, we reported the results of an in vitro pilot study that successfully modeled the ability of Sigyn Therapy to address inflammatory CytoVesicles, which have been elusive targets for previous therapeutic candidates. As a result, we now have pre-clinical insight that Sigyn Therapy can address a broad-spectrum of inflammatory targets, including inflammatory cytokines, endotoxin and CytoVesicles that participate in concert with freely circulating cytokines to escalate Cytokine Storm Syndrome.
The data resulting from these and a series of forthcoming studies will be incorporated into an Investigational Device Exemption (IDE) that we plan to submit to the United States Food and Drug Administration (FDA) in 2021.
Beyond the continued advancement of our clinical endeavors, we also recognize the need to establish a market for our securities, which are thinly traded at present. I am not naïve to this challenge as I previously navigated Aethlon Medical from single-shareholder start-up to Nasdaq-traded Company with 8000+ shareholders and a peak-market value that reached $200 million during my tenure as Chairman and CEO.
Similar to our pathway to the public markets, Aethlon established itself as a public company through a merger with an OTC-traded entity.
I look forward to keeping you updated on our endeavors to advance Sigyn Therapy.
Sincerely,
Jim Joyce
Co-founder, Chairman and CEO
Sigyn Therapeutics, Inc.
About Sigyn Therapeutics
Sigyn Therapeutics is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.
Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.
To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) the outcome of any legal proceedings that may be instituted against Sigyn related to the merger agreement or the transaction. Further risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements are discussed in “Risk Factors” and elsewhere in the previous Reign Resources Corporation Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and other reports filed with the SEC. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.
Contact Sigyn Therapeutics, Inc.
Jim Joyce
Chairman, CEO
(619) 368-2000
jj@sigyntherapeutics.com
$SIGY Sigyn Therapeutics (SIGY) CEO Note: Overcoming the Limitations of Previous Cytokine Storm Treatment Strategies
Press Release | 01/12/2021
SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), today released the following note authored by its Chairman and CEO, Jim Joyce.
Dear Current and Candidate Shareholders,
We created Sigyn Therapy to address a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome (the Cytokine Storm). An annual market opportunity that exceeds $20 billion.
Based on our cumulative experience in developing first-in-industry medical technologies, we designed Sigyn Therapy to overcome the limitations of previous strategies to treat cytokine storm related conditions, yet still optimize patient safety and support widespread deployment.
As anti-cytokine drug mechanisms are limited to single cytokine targets, our focus was directed toward overcoming the limitations of two industry pioneering devices that are market cleared and broadly deployed to treat life-threatening inflammatory conditions outside of the U.S. At present, both of these devices are being evaluated in the U.S. as candidates to treat severe COVID-19 infection.
The first device incorporates an adsorbent bead to address inflammatory cytokines that circulate freely in the blood. However, this device does not address endotoxin, which is a potent activator of cytokine storm syndrome. Conversely, the second device depletes the presence of circulating endotoxin, but does not address inflammatory cytokines. The cytokine device underlies a Nasdaq traded company whose market value is ~$385 million. The endotoxin device is among a family of products marketed by an OTC traded company valued at almost $10 billion.
Since establishing ourselves as a public company on October 19, 2020, we have made considerable progress in collecting relevant data that reinforces the prospect of Sigyn Therapy overcoming the limitations of these products.
On November 2, 2020, I authored my first CEO note entitled: “Rethinking the Treatment of Sepsis and Other Life-Threatening Inflammatory Conditions.” The note disclosed that we had initiated an in vitro study to validate whether Sigyn Therapy could reduce the presence of inflammatory cytokines and endotoxin from human blood plasma.
On December 1, 2020, we reported in vitro study results that validated the ability of Sigyn Therapy to simultaneously clear both inflammatory cytokines and endotoxin from human blood plasma. Beyond reporting this milestone achievement, we disclosed our intent to further evaluate the ability of Sigyn Therapy to address CytoVesicles (extracellular vesicles) that transport inflammatory cytokine cargos throughout the bloodstream.
On January 6, 2021, we reported the results of an in vitro pilot study that successfully modeled the ability of Sigyn Therapy to address inflammatory CytoVesicles, which have been elusive targets for previous therapeutic candidates. As a result, we now have pre-clinical insight that Sigyn Therapy can address a broad-spectrum of inflammatory targets, including inflammatory cytokines, endotoxin and CytoVesicles that participate in concert with freely circulating cytokines to escalate Cytokine Storm Syndrome.
The data resulting from these and a series of forthcoming studies will be incorporated into an Investigational Device Exemption (IDE) that we plan to submit to the United States Food and Drug Administration (FDA) in 2021.
Beyond the continued advancement of our clinical endeavors, we also recognize the need to establish a market for our securities, which are thinly traded at present. I am not naïve to this challenge as I previously navigated Aethlon Medical from single-shareholder start-up to Nasdaq-traded Company with 8000+ shareholders and a peak-market value that reached $200 million during my tenure as Chairman and CEO.
Similar to our pathway to the public markets, Aethlon established itself as a public company through a merger with an OTC-traded entity.
I look forward to keeping you updated on our endeavors to advance Sigyn Therapy.
Sincerely,
Jim Joyce
Co-founder, Chairman and CEO
Sigyn Therapeutics, Inc.
About Sigyn Therapeutics
Sigyn Therapeutics is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.
Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.
To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) the outcome of any legal proceedings that may be instituted against Sigyn related to the merger agreement or the transaction. Further risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements are discussed in “Risk Factors” and elsewhere in the previous Reign Resources Corporation Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and other reports filed with the SEC. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.
Contact Sigyn Therapeutics, Inc.
Jim Joyce
Chairman, CEO
(619) 368-2000
jj@sigyntherapeutics.com
$SIGY Sigyn Therapeutics™ Reports Results of Pilot Study to Address Inflammatory CytoVesicles
Press Release | 01/06/2021
Sigyn Therapy™ is a Candidate to Treat Life-Threatening Inflammatory Conditions That Are Not Addressed with Drug Therapies
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company whose focus is the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome (the Cytokine Storm), today announced the results of an in vitro pilot study that successfully modeled the ability of Sigyn Therapy™ to address CytoVesicles that transport inflammatory cytokine cargos in the bloodstream.
Cytokine Storm Syndrome is an excessive response of the immune system that is induced by infectious and non-infectious conditions. A hallmark indicator of Cytokine Storm Syndrome is the excessive or uncontrolled release of pro-inflammatory cytokines, which can lead to multiple organ failure and cause death. The annual market opportunity to address Cytokine Storm related indications exceeds $20 billion and includes sepsis, the most common cause of hospital deaths worldwide. Virus-induced Cytokine Storm Syndrome is a leading cause of death resulting from severe SARS-CoV-2 (COVID-19) infections.
Sigyn Therapy is a proprietary blood purification technology designed to overcome the limitations of previous drug and device candidates to treat acute inflammatory conditions. Incorporated within Sigyn Therapy is a cocktail of adsorbent components with unique binding and capture characteristics to optimize the broad-spectrum depletion of inflammatory targets from the bloodstream. These targets include pro-inflammatory cytokines, endotoxin and CytoVesicles (extracellular vesicles that transport inflammatory cytokine cargos) that participate in concert with freely circulating cytokines to further escalate the Cytokine Storm. CytoVesicles are an important yet previously elusive target as they can be 20-60 times larger than cytokines themselves.
In the in vitro pilot study, 104nm liposomes were utilized as a model system to assess the ability of Sigyn Therapy’s adsorbent components to deplete CytoVesicles from human blood plasma. After a two-hour interaction with Sigyn’s adsorbent components, liposome concentrations in human blood plasma were reduced ~90%. Previously published studies have validated liposomes as a model for the isolation of extracellular vesicles from blood based on the similarity of their size and structural characteristics.
“When we designed Sigyn Therapy, we envisioned a device that could be broadly deployed by the medical community, yet also have expansive first-in-industry capabilities that offer to improve patient outcomes,” stated Jim Joyce, Chairman and CEO of Sigyn Therapeutics. “When considering our previous report that Sigyn Therapy™ clears both endotoxin and inflammatory cytokines from human blood plasma, the observation from our CytoVesicle pilot study further reinforces the potential for our vision to become a therapeutic reality.”
Sigyn Therapy is a single-use device designed for use on the established infrastructure of dialysis and CRRT machines already located in hospitals and clinics worldwide. On December 1, 2020, the Company reported the results of an in vitro study that validated the ability of Sigyn Therapy to simultaneously reduce the presence of endotoxin and relevant pro-inflammatory cytokines, which included Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-a). Endotoxin (lipopolysaccharide or LPS) is a potent mediator implicated in the pathogenesis of sepsis and septic shock. The dysregulated over-production of IL-1B, IL-6 and TNF-a can lead to organ failure and cause death.
An objective of the study was to rebalance elevated cytokine levels and optimize the elimination of endotoxin from human blood plasma. The study was conducted in triplicate over four-hour time periods with a pediatric version of Sigyn Therapy. Average reduction of endotoxin load peaked at 83% during the studies. The average reduction of IL-1B was 69%, IL-6 reduction was 59% and TNF-a reduction was 57% during the four-hour studies.
The resulting data from each of these studies will be incorporated into an Investigational Device Exemption (IDE) that Sigyn Therapeutics plans to submit to the United States Food and Drug Administration (FDA) in 2021.
About Sigyn Therapeutics
Sigyn Therapeutics™ is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.
Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.
To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.
Contact Sigyn Therapeutics, Inc.
Jim Joyce
Chairman, CEO
(619) 368-2000
jj@sigyntherapeutics.com
There are 3 lenders, but they have never been an issue before. It's the new lenders I would be concerned about in June when the restriction is lifted.
Someone should call the new CEO and see what's up.
I don't know, right now there can be no dilution because everyones shares are restricted. I don't want to be holding when that restriction is lifted. Right now it trades like a 200k float. It moves so fast, that 10k vol could easily bring it over $3. When dilution becomes possible, it wont trade like that anymore. At this moment we are sitting on a gold mine (no joke intended there). Later on when those shares become tradeable it will take a lot of volume to move it that far.
yeah the float is really locked up and mostly with one lender and the two founders. With the right news, this could explode. I dont mind waiting.
By the way, I also read that the previous debt carried over by Reign was converted instead into restricted shares. So that's positive. The reason it's probably so quiet right now is because none of the convertible debt can be sold. They wont put money into publicizing information if their shares are restricted.
ok ok ... No its not under their ownership, the previous CEO still has control of that venture though I dont know if he is actively working it or not. Yeah very detailed on the news, may be beyond what most can understand including myself. It could take a while but this will have its day in the sun. I have done some trading over the past few months to help lower my average slightly, not more one can do but wait, I am fine with that.
If you go to OTC Markets under "Filings and Disclosure" the top posting on Dec 11th 2020 says OTCQB Certification.
I think the gold mine purchase is still considered an asset and is now under the ownership of SIGN?
They recently had very good news. It doesn't look like the news was well publicized though.
Where do you see that info that they got upgraded, that sounds familiar but I cant put my finer on it? RGNP used to be on QB but downgraded when they essentially didnt have any business left.
Looks like they got upgraded to QB. That's what it shows on OTC Markets. I don't know how long it takes for that update to take effect.
well SIGY is just stuck here for a while, but I anticipate that will change, I just don't know when but I am ready when it does
I've tried to do some light trading between 1.50 and 2.00 to make some money and give the market makers something to do. I do believe that one day this will just take off but I have no idea when that will be. As far as downside it appears that 1.50 is support, seems safe above that, but you never know.
Rethinking the Treatment of Sepsis and Other Life-Threatening Inflammatory Conditions
SAN DIEGO, CA, Nov. 02, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc.(SIGY) , today released the following note authored by its Chairman and CEO, Jim Joyce.
Dear Current and Candidate Shareholders,
We created Sigyn Therapy™ to address a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome (The Cytokine Storm). The intent of this communication (the first in a series) is to introduce and familiarize you with our technology and therapeutic opportunities, which include large market indications that remain beyond the reach of drug therapies.
Cytokine storm syndrome is characterized as a dysregulated response of the immune system, which can be induced by a wide-range of infectious and non-infectious conditions. Since the outset of the current pandemic, medical journals have widely reported cytokine storm syndrome to be a leading cause of death resulting from severe COVID-19 infections. A hallmark of the cytokine storm is an excessive or uncontrolled release of pro-inflammatory cytokines, which can induce multiple organ failure and result in death.
To recalibrate this dysregulated immune response, we designed Sigyn Therapy to deplete a broad-spectrum of inflammatory contributors from the bloodstream. The most prevalent condition associated with cytokine storm syndrome is sepsis. Earlier this year, the Journal Lancet reported that sepsis kills more people around the world than all forms of cancer combined. The Lancet reported that in 2017, there were 48.9 million cases of sepsis and 11 million deaths. In that same year, the journal reported an estimated 20.3 million sepsis cases and 2.9 million deaths were among children younger than 5 years old. In the United States, sepsis was reported to be the most common cause of in-hospital deaths and accounted for more than $24 billion in annual costs.
To date, more than 70 controlled human studies have been conducted to evaluate the safety and benefit of candidate drugs to treat sepsis. With one brief exception (Xigris from Eli Lilly), none of these studies resulted in an approved drug therapy. When considering the breadth of contributing inflammatory factors, sepsis is likely to remain an elusive target for therapeutic drug agents.
As a result of this therapeutic void, a significant opportunity for non-pharmaceutical blood purification devices has emerged. In this regard, I encourage you to learn about CytoSorbents Corporation and Toray Industries, Inc. Both are publicly-traded organizations that we highly respect for the advancement of their respective CytoSorb and Toraymyxin devices. Each of these industry pioneering devices are market cleared and broadly deployed to treat a wide-range of inflammatory conditions outside of the U.S. They are being clinically evaluated in the U.S. as candidates to treat severe COVID-19 infection under FDA-awarded Emergency Use Authorizations.
In regards to mechanism of action, Toraymyxin has a high specificity to bind circulating endotoxin, which is reported to be a potent activator of cytokine storm syndrome. However, the Toraymyxin device does not address pro-inflammatory cytokines. Conversely, the CytoSorb device incorporates an adsorbent component that depletes pro-inflammatory cytokines from circulation, but does not address endotoxin.
We designed Sigyn Therapy to deplete the presence of both endotoxin and pro-inflammatory cytokines. To further optimize the potential of our therapeutic outcomes, we expanded Sigyn Therapy’s mechanism to include the elimination of larger proteins that transport cytokines and other inflammatory cargos. We refer to these as CytoVesicles. To address this breadth of targets, we incorporate a cocktail of adsorbent components within Sigyn Therapy that each have unique binding and capture characteristics.
In the medical field, the term cocktail often refers to the simultaneous administration of multiple drugs with differing mechanisms of action. However, the dosing of multiple drugs is limited by toxicity and adverse events that may result from deleterious drug interactions. Sigyn Therapy is not constrained by such limitations as our cocktail of adsorbent components are not introduced into the body. As a result, we are able to incorporate a substantial dose of multiple adsorbents, each with differing mechanisms and capabilities to optimize the ability of Sigyn Therapy to calm the cytokine storm that underlies life-threatening inflammatory conditions.
Our therapeutic opportunities include, but are not limited to sepsis, virus induced Cytokine Storm (VICS), bacteria induced Cytokine Storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, including hepatic encephalopathy.
To translate our therapeutic vision into a clinical reality, we are planning a series of studies whose outcomes will be included in an Investigational Device Exemption (IDE) that we intend to submit to FDA in 2021. At present, we are conducting an in vitro study designed to validate the ability of Sigyn Therapy to simultaneously reduce the presence of endotoxin and relevant pro-inflammatory cytokines from human blood plasma. In this study, our cytokine targets include interleukin-6 (IL-6), interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-a), which are each drug industry targets to treat COVID-19 infected individuals.
Roche, Sanofi, Regeneron and EUSA Pharma are evaluating anti-IL-6 drugs as COVID-19 treatment candidates. Additionally, SOBI is testing an IL-1 inhibitor and Amgen is evaluating the potential benefit of Enbrel to inhibit TNF-a in COVID-19 infected individuals. The prospect of aligning a therapeutic drug with a specific cytokine may be limited as researchers at Stanford and Yale have reported that cytokine profiles in those suffering from severe COVID-19 infection to be consistent with those previously observed in sepsis patients. We believe that a device with much broader capabilities will be required.
I look forward to keeping you updated on our endeavors to advance Sigyn Therapy.
Sincerely,
Jim Joyce
Chairman and CEO
Sigyn Therapeutics, Inc.(SIGY)
About Sigyn Therapeutics(SIGY)
Sigyn Therapeutics (SIGY) is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.
Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.
To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of Sigyn Therapeutics, Inc.(SIGY) (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) the outcome of any legal proceedings that may be instituted against Sigyn related to the merger agreement or the transaction. Further risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements are discussed in “Risk Factors” and elsewhere in the previous Reign Resources Corporation Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and other reports filed with the SEC. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.
Contact Sigyn Therapeutics, Inc.(SIGY)
Jim Joyce
Chairman, CEO
(619) 368-2000
jimjoyce@elevatescience.com
well this has been a complete dud since the transaction went thru. At this point I think we may need some news or anticipation of some news to propel this, so be it.
$SIGY : REIGN is now SIGYN
just happened
GO $SIGY
Very curious to see where this goes. Grabbed a 5k lotto
this should be fun, very very fun. Looking forward to see how this trades this week and ongoing.
Wow, great find. That was fast!
Reign Resources Corp., RGNP, changed to Sigyn Therapeutics Inc., SIGY:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
Hang tight everyone, a buck fifty is going to sound like chump change when this takes off, at least we should start off with a double and go from there, we should be very close. Remember that whatever the OS count turns out to be, it's held mostly by the founders and old lenders who want much higher prices.
Scumbag mm manipulation as usual
Look at ARCAs wash trade
1716 1.785
1716 1.97
LOL
Wait til it’s a 500k day
After the symbol change, this stock could easily go above twenty dollars a share. Due to having a very low float, and being in the biotechnology sector.
Appears to have settled around $1.60 where I have been accumulating. I expect a pop back towards 3 bucks as soon as the final pronouncement is done that the deal is done, which I expect in the next few days or so per the last filing .
Some interesting company highlights: Upon completion of the merger, Reign will be renamed Sigyn Therapeutics, Inc. and will be led by Sigyn co-founder Jim Joyce, who will serve as Chairman and CEO of the combined company. Sigyn Therapeutics will be focused on addressing a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome ("The Cytokine Storm" or "CSS") and not addressed with an approved therapy. The annual market opportunity for a therapeutic strategy to prevent or mitigate CSS has been reported to exceed $20 billion. Additional announcements regarding the combined company's management structure, Board of Directors and Science Advisory Board will be forthcoming.
Sigyn Therapy(TM) is a development-stage blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory conditions, including sepsis, which is the #1 cause of hospital deaths. The mechanism of Sigyn Therapy allows for a broad-spectrum of inflammatory targets to be depleted from the bloodstream. Among the targets are inflammatory cytokines, cytokine aggregates, endotoxin and CytoVesicles that transport cytokines and other inflammatory cargos.
Beyond sepsis, Cytokine Storm related therapeutic opportunities include, but are not limited to virus induced Cytokine Storm (a leading cause of COVID-19 deaths), bacteria induced Cytokine Storm, acute respiratory distress syndrome (ARDS) and acute forms of liver failure, including hepatic encephalopathy. Sigyn Therapy may also be a candidate to stabilize or extend the life of patients waiting for the identification of a matched liver for transplantation. In such a scenario, Sigyn Therapy(TM) would serve as a bridge-to-liver transplant. Cytokine Storm Syndrome can also result from trauma, severe burns, acute pancreatitis, adverse drug reactions, cancer immunotherapies, cancer cachexia, acute kidney injury (AKI) and severe pneumonia.
This should really take off after the new stock symbol change. This is only the beginning.
Strong price action today. A close above $2.00 should send this rocketing.
things appear to be moving forward with todays filing. Added another 1000 shares today. Wow thats .006/share pre-split for those of you old guys, wow.
I take that back, my order is NOT yet filled, just bidding at .90, sorry about that but hopefully will get filled.
So that the new owner has majority shareholder status.
Followers
|
16
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
839
|
Created
|
12/02/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |